Lupin's Nagpur facility receives six FDA observations

Lupin Limited announced that the U.S. FDA conducted an inspection of its Nagpur injectable facility from September 8 to September 16, 2025. The inspection concluded with six observations.

The company stated its commitment to addressing these observations and will respond to the U.S. FDA within the stipulated timeframe. Lupin emphasized its dedication to complying with CGMP quality standards across all its facilities.